News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
691,377 Results
Type
Article (39366)
Company Profile (255)
Press Release (651756)
Section
Business (204174)
Career Advice (2006)
Deals (35422)
Drug Delivery (89)
Drug Development (80998)
Employer Resources (169)
FDA (16128)
Job Trends (14836)
News (345102)
Policy (32486)
Tag
Academia (2531)
Alliances (49356)
Alzheimer's disease (1299)
Approvals (16095)
Artificial intelligence (179)
Bankruptcy (354)
Best Places to Work (11630)
Biotechnology (182)
Breast cancer (214)
Cancer (1592)
Cardiovascular disease (122)
Career advice (1669)
CAR-T (112)
Cell therapy (323)
Clinical research (65107)
Collaboration (608)
Compensation (313)
COVID-19 (2561)
C-suite (141)
Data (1511)
Diabetes (194)
Diagnostics (6236)
Earnings (85151)
Employer resources (146)
Events (110659)
Executive appointments (516)
FDA (16943)
Funding (548)
Gene therapy (226)
GLP-1 (633)
Government (4348)
Healthcare (18757)
Infectious disease (2659)
Inflammatory bowel disease (115)
Interviews (310)
IPO (16432)
Job creations (3635)
Job search strategy (1421)
Layoffs (430)
Legal (7879)
Lung cancer (234)
Manufacturing (221)
Medical device (13246)
Medtech (13251)
Mergers & acquisitions (19296)
Metabolic disorders (513)
Neuroscience (1678)
NextGen: Class of 2025 (6518)
Non-profit (4474)
Northern California (1923)
Obesity (293)
Opinion (188)
Patents (138)
People (56784)
Phase I (20281)
Phase II (28677)
Phase III (21352)
Pipeline (638)
Postmarket research (2563)
Preclinical (8572)
Radiopharmaceuticals (240)
Rare diseases (301)
Real estate (5907)
Regulatory (21852)
Research institute (2312)
Resumes & cover letters (350)
Southern California (1664)
Startups (3574)
United States (17237)
Vaccines (589)
Weight loss (200)
Date
Last 7 days (622)
Last 30 days (2587)
Last 365 days (34686)
2025 (2656)
2024 (35252)
2023 (40104)
2022 (51230)
2021 (55762)
2020 (54126)
2019 (46568)
2018 (35042)
2017 (32144)
2016 (31522)
2015 (37590)
2014 (31361)
2013 (26382)
2012 (28585)
2011 (29284)
2010 (27353)
Location
Africa (713)
Arizona (206)
Asia (37508)
Australia (6141)
California (4404)
Canada (1603)
China (369)
Colorado (199)
Connecticut (210)
Europe (80319)
Florida (633)
Georgia (154)
Illinois (432)
Indiana (249)
Maryland (701)
Massachusetts (3389)
Michigan (188)
Minnesota (323)
New Jersey (1243)
New York (1266)
North Carolina (801)
Northern California (1923)
Ohio (161)
Pennsylvania (1034)
South America (1093)
Southern California (1664)
Texas (645)
Utah (129)
Washington State (436)
691,377 Results for "protalix biotherapeutics inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Protalix BioTherapeutics to Present at the 2024 BIO International Convention
Protalix BioTherapeutics, Inc. announced that Dror Bashan, its President and Chief Executive Officer, will present at the upcoming 2024 BIO International Convention June 3 - 6, 2024, in San Diego, California.
May 29, 2024
·
3 min read
Business
Protalix BioTherapeutics Reports First Quarter 2024 Financial and Business Results
Protalix BioTherapeutics, Inc., a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, reported financial results for the quarter ended March 31, 2024, and provided a business and clinical update.
May 10, 2024
·
15 min read
Protalix BioTherapeutics to Host In-Person Investor Day to Discuss Current Treatment Landscapes and Clinical Results for Fabry Disease and Uncontrolled Gout
Protalix BioTherapeutics, Inc. announced that it will host an in-person investor day at the Lotte Palace New York Hotel in New York on Wednesday, June 26, 2024 at 8:30 a.m. Eastern Daylight Time.
June 13, 2024
·
5 min read
Business
Protalix BioTherapeutics Reports Fiscal Year 2023 Financial and Business Results
Protalix BioTherapeutics, Inc. reported financial results for the fiscal year ended December 31, 2023, and provided a business update.
March 14, 2024
·
18 min read
Press Releases
Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce Validation of Variation Submission by European Medicines Agency for pegunigalsidase alfa
December 10, 2024
·
10 min read
Business
Protalix BioTherapeutics to Announce First Quarter 2024 Financial and Business Results on May 10, 2024
Protalix BioTherapeutics, Inc., a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell–based protein expression system, announced that it will release its financial results for the quarter ended March 31, 2024 and provide a business and clinical update on May 10, 2024.
May 3, 2024
·
2 min read
Protalix BioTherapeutics to Participate in the 2024 BIO CEO & Investor Conference
Protalix BioTherapeutics, Inc. (NYSE American: PLX) today announced that it will attend and present at the 2024 BIO CEO & Investor Conference taking place February 26-27, 2024 at the New York Marriott Marquis in New York City.
February 23, 2024
·
2 min read
Business
Protalix BioTherapeutics to Announce Fiscal Year 2023 Financial and Business Results on March 14, 2024
Protalix BioTherapeutics, Inc. today announced that it will release its financial results for the fiscal year ended December 31, 2023 and provide a business update on Thursday, March 14, 2024.
March 7, 2024
·
2 min read
Business
Protalix BioTherapeutics Reports Third Quarter 2023 Financial and Business Results
Protalix BioTherapeutics, Inc. reported financial results for the third quarter ended September 30, 2023 and provided a business update on recent regulatory, clinical and corporate developments.
November 6, 2023
·
16 min read
Business
Protalix BioTherapeutics to Announce Third Quarter 2023 Financial and Business Results on November 6, 2023
Protalix BioTherapeutics, Inc. (NYSE American:PLX) today announced that it will release its financial results for the third quarter ended September 30, 2023 and provide a business update on Monday, November 6, 2023.
October 30, 2023
·
3 min read
1 of 69,138
Next
